It is made available under a CC-BY-NC-ND 4.0 International license .

Heterozygous loss-of-function *SMC3* variants are associated with variable and incompletely penetrant growth and developmental features

Morad Ansari^{1,2,39}, Kamli N. W. Faour^{3,4,39}, Akiko Shimamura⁵, Graeme Grimes², Emeline M. Kao⁶, Erica R. Denhoff⁶, Ana Blatnik^{2,7}, Daniel Ben-Isvy^{8,9,10}, Lily Wang^{8,9,10}, Benjamin M. Helm¹¹, Helen Firth¹², Amy M. Breman¹¹, Emilia K. Bijlsma¹³, Aiko Iwata-Otsubo¹¹, Thomy J.L. de Ravel¹⁴, Vincent Fusaro¹⁵, Alan Fryer¹⁶, Keith Nykamp¹⁵, Lara G. Stühn¹⁷, Tobias B. Haack¹⁷, G. Christoph Korenke¹⁸, Panayiotis Constantinou¹⁹, Kinga M. Bujakowska²⁰, Karen J. Low^{21,22}, Emily Place²⁰, Jennifer Humberson²³, Melanie P. Napier²⁴, Jessica Hoffman²⁴, Jane Juusola²⁴, Matthew A. Deardorff²⁵, Wanqing Shao²⁶, Shira Rockowitz^{26,27,3}, Ian Krantz²⁸, Maninder Kaur²⁸, Sarah Raible²⁸, Sabine Kliesch²⁹, Moriel Singer-Berk⁹, Emily Groopman^{3,9}, Stephanie DiTroia⁹, Sonia Ballal^{4,30}, Siddharth Srivastava^{4,31}, Kathrin Rothfelder³², Saskia Biskup^{32,33}, Jessica Rzasa³⁴, Jennifer Kerkhof³⁴, Haley McConkey³⁴, Anne O'Donnell-Luria^{3,8,9}, Bekim Sadikovic³⁴, Sarah Hilton³⁵, Siddharth Banka³⁵, Frank Tüttelmann³⁶, Donald Conrad^{37,38}, Michael E. Talkowski^{9,8}, David R. FitzPatrick^{2,40}, Philip M. Boone^{4,3,8,9,40,*}

¹South East Scotland Genetic Service, Western General Hospital, Edinburgh, UK, ²MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK, ³Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, US, ⁴Cornelia de Lange Syndrome and Related Disorders Clinic, Boston Children's Hospital, Boston, MA, US, ⁵Division of Hematology and Oncology, Boston Children's Hospital, Boston, MA, US, ⁶Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, US, ⁷Department of Clinical Cancer Genetics, Institute of Oncology Ljubljana, Ljubljana, SI, ⁸Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, US, ⁹Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, US, ¹⁰Division of Medical Sciences, Harvard Medical School, Boston, MA, US, ¹¹Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, US, ¹²Clinical Genetics, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK, ¹³Department of Clinical Genetics, Leiden University Medical Centre, Leiden, NL, ¹⁴Centre for Human Genetics, UZ Leuven/ Leuven University Hospitals, Leuven, BE, ¹⁵Invitae, San Francisco, CA, US, ¹⁶Department of Clinical Genetics, Alder Hey Children's Hospital Liverpool, Liverpool, UK, ¹⁷Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, DE, ¹⁸University Children's Hospital Oldenburg, Department of Neuropaediatric and Metabolic Diseases, University Children's Hospital Oldenburg, Oldenburg, DE, ¹⁹West of Scotland Centre for Genomic Medicine, Queen Elizabeth University Hospital, Glasgow, UK, ²⁰Massachusetts Eye and Ear Infirmary, Boston, MA, US, ²¹University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK, ²²University of Bristol, Bristol, UK, ²³University of Virginia Health System, Charlottesville, VA, US, ²⁴GeneDx, Gaithersburg, MD, US, ²⁵Departments of Pathology and Pediatrics, Children's Hospital Los Angeles and University of Southern California, Los Angeles, CA, US, ²⁶Research Computing, Information Technology, Boston Children's Hospital, Boston, MA, US, ²⁷The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA, US, ²⁸Children's Hospital of Philadelphia, Philadelphia, PA, US, ²⁹Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, University Hospital Münster, Münster, DE, ³⁰Division of Gastroenterology, Boston Children's Hospital, Boston, MA, US, ³¹Divison of Neurology, Boston Children's Hospital, Boston, MA, US, ³²Zentrum für Humangenetik, Tübingen, DE, ³³Center for Genomics and Transcriptomics (CeGaT), Tübingen, DE, ³⁴Molecular Diagnostics Program and Verspeeten Clinical Genome Centre, LHSC, London, CA, ³⁵Manchester University, Manchester, UK, ³⁶Institute of Reproductive Genetics, University of Münster, Münster, DE, ³⁷Division of Genetics, Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR, US, ³⁸Center for Embryonic Cell and Gene Therapy, Oregon Health and Science University, Portland, OR, US, ³⁹These authors contributed equally, ⁴⁰These authors contributed equally.

*Correspondence: Dr. Philip M. Boone Cornelia de Lange Syndrome and Related Disorders Clinic Boston Children's Hospital 300 Longwood Ave. Boston, MA, USA 02115 Tel: +1 (617) 355-6394 E-mail: philip.boone@childrens.harvard.edu

It is made available under a CC-BY-NC-ND 4.0 International license .

1 Abstract

2 Heterozygous missense variants and in-frame indels in SMC3 are a cause of Cornelia 3 de Lange syndrome (CdLS), marked by intellectual disability, growth deficiency, and 4 dysmorphism, via an apparent dominant-negative mechanism. However, the spectrum of 5 manifestations associated with SMC3 loss-of-function variants has not been reported, leading 6 to hypotheses of alternative phenotypes or even developmental lethality. We used 7 matchmaking servers, patient registries, and other resources to identify individuals with 8 heterozygous, predicted loss-of-function (pLoF) variants in SMC3, and analyzed population 9 databases to characterize mutational intolerance in this gene. Here, we show that SMC3 10 behaves as an archetypal haploinsufficient gene: it is highly constrained against pLoF 11 variants, strongly depleted for missense variants, and pLoF variants are associated with a 12 range of developmental phenotypes. Among 13 individuals with SMC3 pLoF variants, 13 phenotypes were variable but coalesced on low growth parameters, developmental 14 delay/intellectual disability, and dysmorphism reminiscent of atypical CdLS. Comparisons to 15 individuals with SMC3 missense/in-frame indel variants demonstrated a milder presentation 16 in pLoF carriers. Furthermore, several individuals harboring pLoF variants in SMC3 were 17 nonpenetrant for growth, developmental, and/or dysmorphic features, some instead having 18 intriguing symptomatologies with rational biological links to SMC3 including bone marrow 19 failure, acute myeloid leukemia, and Coats retinal vasculopathy. Analyses of transcriptomic 20 and epigenetic data suggest that SMC3 pLoF variants reduce SMC3 expression but do not 21 result in a blood DNA methylation signature clustering with that of CdLS, and that the global 22 transcriptional signature of SMC3 loss is model-dependent. Our finding of substantial 23 population-scale LoF intolerance in concert with variable penetrance in subjects with SMC3 24 pLoF variants expands the scope of cohesinopathies, informs on their allelic architecture, and

- 25 suggests the existence of additional clearly LoF-constrained genes whose disease links will
- 26 be confirmed only by multi-layered genomic data paired with careful phenotyping.
- 27 Keywords: Cornelia de Lange syndrome, SMC3, loss-of-function, cohesin, CdLS3, LoF

It is made available under a CC-BY-NC-ND 4.0 International license .

28 Introduction

29 The cohesin complex, a multimeric structure with the ability to entrap DNA, is integral to several dynamic genome processes.^{1,2} Specifically, cohesin facilitates sister 30 chromatid cohesion during cell division,³ DNA repair,⁴ 3D chromatin architecture,⁵ and 31 transcriptional control of developmental genes.^{6,7} SMC3 (structural maintenance of 32 chromosomes 3), the sole subunit shared by mitotic, interphase, and meiotic cohesin, is a 33 34 ubiquitously expressed protein that binds with SMC1A/B to form the legs of the isosceles 35 triangle commonly used to represent the closed heterotrimeric cohesin 'ring,' with 36 RAD21/REC8 forming the base.

In mouse models, homozygous *SMC3* loss^{8,9} or conditional *SMC3* depletion in oocytes¹⁰ results in embryonic lethality. In embryonic and adult mice, homozygous *SMC3* loss in the blood compartment causes myeloid-based hematopoietic failure.^{11,12} However, *SMC3* heterozygosity in mice is tolerated and associated with behavioral phenotypes, neuronal/synaptic differences in the cerebral cortex, decreased body weight, craniofacial dysmorphism, and changes in gene expression,^{8,9} suggesting the potential for a similar phenomenon in humans.¹³

44 Missense variants and in-frame indels in SMC3 have been identified among patients with mild/atypical Cornelia de Lange syndrome (CdLS).¹³⁻¹⁵ Typical (classic) CdLS is caused 45 46 by constitutional or mosaic heterozygous loss-of-function (LoF) pathogenic variants in 47 *NIPBL* and is distinguished from atypical CdLS, which is a spectrum, by greater overall 48 severity with a more characteristic facial appearance and the presence of major 49 malformations. Variable intellectual disability, behavioral abnormalities, hirsutism, growth 50 failure, gastroesophageal dysfunction, and short first metacarpals are seen in both typical and 51 atypical cases. SMC3-related CdLS is principally marked by intellectual disability, facial dysmorphism, microcephaly, and postnatal growth delay.¹³⁻¹⁶ 52

53 The reported missense variants and in-frame indels in SMC3 generally fall within important protein regions including the antiparallel coiled-coil, hinge, and head domains.¹⁴ 54 55 Tested pathogenic variants appear to act as dominant-negative alleles in human cell lines, 56 where they increase the affinity of SMC hinge dimers for DNA, promoting genome instability and impairing genomic spatial organization.¹⁷ In silico modeling is also consistent 57 with a dominant-negative effect.¹⁴ Furthermore, proteomic analyses reveal that missense-58 59 mutated SMC3 proteins are incorporated into the cohesin complex normally but prompt 60 dysregulation of the c-MYC transcription factor, a feature of CdLS in the early prenatal 61 period.¹⁸ Finally, SMC3 missense variants in CdLS patients confer a DNA methylation 62 episignature grouping with that of other CdLS genes.¹⁹

63 There is considerable importance of allele type in other cohesin genes, for example NIPBL (missense in mild CdLS vs LoF in severe CdLS²⁰⁻²²) and SMC1A (missense in 64 atypical CdLS vs LoF in SMC1A-related developmental and epileptic encephalopathy²³). 65 66 Thus, it has been proposed that the absence of SMC3 predicted LoF (pLoF) variants in 67 previously described CdLS cases could be due to those variants either causing a different phenotype or being lethal for the developing embryo.²⁴ Somatic SMC3 pLoF variants have 68 been found in myeloid malignancies,²⁵ including acute myeloid leukemia²⁶ and Down 69 syndrome acute megakaryoblastic leukemia.^{27,28} This is in line with LoF alleles in cohesin 70 71 genes being a common event in several tumor types, not as initiating events but as subsequent drivers.²⁹ Population genetic data suggest that germline *SMC3* pLoF variants are considerably 72 73 depleted in the general population 74 (https://gnomad.broadinstitute.org/gene/ENSG00000108055); however, the consequence of 75 heterozygous germline pLoF variants in humans is unknown, as only a single case is 76 documented in the literature.¹⁵

It is made available under a CC-BY-NC-ND 4.0 International license .

77 Here, we describe the clinical phenotypes of 13 individuals with germline pLoF 78 variants in SMC3, including four frameshifts, four stop gains, four deletions, and one 79 predicted damaging splice variant. Many, but not all, individuals have developmental delay, 80 low growth parameters, and/or mild dysmorphism - reminiscent of atypical CdLS. 81 Comparisons of quantitative growth and developmental data between pLoF carriers and published cases of SMC3 pathogenic missense variants and in-frame indels reveal a 82 83 genotype-phenotype correlation, with pLoF conferring milder - albeit overlapping -84 parameters. We also observe several individuals without growth or neurodevelopmental 85 abnormalities and test multiple hypotheses to explain this incongruity. Our findings suggest 86 that a broader class of undiscovered Mendelian conditions stemming from LoF variants in 87 highly constrained genes likely remains uncatalogued owing to generic, variable, and/or 88 incompletely penetrant phenotypes and will require large dataset analyses, deep phenotyping, 89 and functional experimentation to solve.

90 Subjects and Methods

91 *Case recruitment*

92 Anonymized genetic and phenotypic information was collected, subjects were 93 enrolled, and database searches performed under Boston Children's Hospital IRB-approved 94 protocol #00040134. Multiple sources were queried to identify individuals with predicted loss of function variants in SMC3: ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/):³⁰ 95 GeneMatcher/Matchmaker Exchange (https://genematcher.org/);³¹ the Baylor Genetics, 96 97 GeneDx, Indiana University School of Medicine Genetic Testing, and Invitae clinical laboratories; a database of patients at Boston Children's Hospital;³² an in-house data portal 98 99 built upon seqr³³ and drawing from the Broad Institute Center for Mendelian Genomics and GREGoR Consortium projects; DECIPHER (https://www.deciphergenomics.org);³⁴ and one 100

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.23294269; this version posted September 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 101 previously-published individual with an SMC3 nonsense variant referred for routine CdLS
- 102 screening due to CdLS-like features and developmental delay.¹⁵
- 103 Growth and developmental milestone comparisons
- 104 Growth measurements were converted to Z-scores using the British Growth Survey
- 105 data (https://www.rcpch.ac.uk/resources/growth-charts). Statistical comparisons and plot
- 106 generation were undertaken using R.
- 107 Subject variant identification

108 Variants were identified via exome sequencing, microarray, or gene panel. These
109 methods are listed for each case in Table S1, as is the confirmation status of variants by
110 orthogonal methods.

111 *Gene annotations*

112 RefSeq transcript NM 005445 (Gencode ENST0000361804.5), via 113 (https://genome.ucsc.edu/) was used as the gene model for analyses. The Ensembl Variant 114 Effect Predictor (https://useast.ensembl.org/Tools/VEP) was used to corroborate subjects' 115 variant nomenclature. Regional missense constraint for SMC3 was based on gnomAD data 116 threshold of p=0.001and assessed а in at as https://www.biorxiv.org/content/10.1101/148353v1 and ³⁵. The region of potential escape 117 118 from nonsense mediated decay was considered as the final 55 nt of the penultimate exon of 119 SMC3 (codon 1176 and beyond). GRCh38/hg38 is the default genome build used unless 120 specified otherwise.

121 UK Biobank pLoF sequence variant curation

It is made available under a CC-BY-NC-ND 4.0 International license .

122 The 10-110575403-TGTGA-T splice site variant, present in 5 individuals in the 123 UKBB, was removed from the list of *SMC3* pLoF variants in UKBB; this is on account of it 124 not resulting in an alteration to the first 5 nt of the 5' splice site.

125 *Copy-number variant detection among UK Biobank samples*

126 UKBB SMC3 deletions were called using GATK-gCNV with genomic interval 127 selection. sample processing, and defragmentation performed in as 128 (https://www.biorxiv.org/content/10.1101/2022.08.25.504851v1). In brief, exome sequencing 129 reads were first mapped to a predefined set of genomic intervals curated to capture the exonic 130 regions of canonical protein-coding genes, and coverage was collected across well-captured 131 intervals for copy number (CN) inference. Samples with similar global read depth profiles 132 were then clustered into batches to be jointly processed by GATK-gCNV, which outputs 133 CNV calls across the set of well-captured intervals. These raw calls were subsequently 134 defragmented, and to ensure that calls were not merged across high-quality CN=2 regions, 135 CNVs were refragmented to preserve any CN=2 segments spanning at least 3 exome 136 sequencing probes with quality score (QS) \geq 100. Finally, the resulting callset was refined 137 using the recommended QS, sample-level, and site frequency filters from 138 (https://www.biorxiv.org/content/10.1101/2022.08.25.504851v1) along with a filter to 139 remove CNVs covering fewer than 3 exons.

140 Infertility cohort missense burden analysis

141 Comparisons were made to gnomAD v2.1.1 missense SMC3 variants with CADD 142 >25 S4) assigned Effect score (Table as by the Variant Predictor 143 (https://useast.ensembl.org/info/docs/tools/vep/index.html). The cumulative allele frequency 144 was transformed to a fraction with a denominator representing the mean number of alleles 145 across these variants, for the purpose of chi-square analysis.

It is made available under a CC-BY-NC-ND 4.0 International license .

146 *Gene expression analyses*

147	SMC3 gene expression data were derived from Cancer Cell Line Encyclopedia
148	(CCLE) samples, restricted to hematopoietic and lymphoid tumors, obtained via
149	(http://xenabrowser.net). Nonsense, frameshift, or splice site variants were considered
150	predicted loss-of-function (pLoF). Samples containing >1 SMC3 variant were categorized by
151	the most damaging variant class. Samples solely containing missense or silent SMC3 variants
152	were removed, as were samples lacking SMC3 genotype or expression data.

153 Perturb-seq data were derived from Replogle et al.³⁶ and obtained via

154 (https://plus.figshare.com/articles/dataset/_Mapping_information-rich_genotype-

155 <u>phenotype_landscapes_with_genome-scale_Perturb-seq_Replogle_et_al_2022_-</u>

156 <u>commonly_requested_supplemental_files/21632564/1</u>) and (<u>https://gwps.wi.mit.edu/</u>).

157 Briefly, this Perturb-seq experiment involved single-cell sequencing following pooled, 158 multiplexed CRISPR interference (CRISPRi) in three parallel approaches, each using a 159 different CRISPRi guide library: K562 (chronic myelogenous leukemia, female) cells 160 receiving a genome-wide guide library against all expressed genes and harvested on day 8 161 after transduction; K562 cells receiving a DepMap essential gene guide library and harvested 162 on day 6 after transduction; and hTERT RPE1 (retinal pigment epithelium, female) cells 163 receiving a DepMap essential gene guide library and harvested on day 7 after transduction. 164 Each library vector construct encoded two guides (sgRNAs) per target gene.

Smc3^{+/-} mouse cortex differentially expressed genes from RNA sequencing were obtained from Fujita et al.⁸ *Nipb1*^{+/-} whole brain RNA sequencing data were obtained from Kean et al.³⁷ In comparisons of these datasets, a denominator of 30,686 genes (see Fig. 3d) was established from among the 55,228 total genes mapped in Kean et al.³⁷ (GEO entry: <u>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203014</u>) based on those having 10 or more reads across all 22 samples, which was the cutoff used in the original analysis.

It is made available under a CC-BY-NC-ND 4.0 International license .

171

Statistical analyses were conducted in R. Key gene lists are in Table S5.

172 DNA methylation analysis

DNA from blood was subjected to array-based methylation analysis via the Manchester EpiPro project (<u>https://mft.nhs.uk/nwglh/test-information/rare-disease/epipro-</u> <u>project/</u>). The genome-wide DNA methylation profile was compared to the EpiSign Knowledge Database, a collection of DNA methylation signatures specific for rare disorders, as in Aref-Eshghi et al.¹⁹

178 **Results**

179 *Case series and subject phenotypes*

180 Thirteen individuals with SMC3 predicted loss of function (pLoF) variants were 181 identified. Most subjects underwent genetic testing as part of routine clinical assessment for 182 growth retardation, developmental delay, and/or dysmorphic features. In only three cases was 183 there clinical suspicion of CdLS. Some cases were identified via diagnostic laboratories, 184 research repositories, hospital-based databases, and GeneMatcher. Subjects possessed 185 frameshift indel, deletion, stop gain, or splice variants (Tables 1, S1; Fig. 1). Of these 13 186 variants, five were *de novo*, one was maternally inherited, two were paternally inherited, and 187 six were of unknown inheritance. Adjudication of the nine SNVs using an advanced LoF 188 curation framework (https://www.medrxiv.org/content/10.1101/2023.03.08.23286955v1) 189 flagged two as potentially not having a LoF effect (one splice variant and one escape from 190 nonsense mediated decay) (Table S1). Missense variants were specifically excluded, as 191 missense variant effects (e.g., hypomorphic vs nullimorphic vs dominant negative) are unable 192 to be reliably predicted.

193 Information on individual patients' clinical features can be acquired by contacting the 194 corresponding authors. This information will be included in a future peer-reviewed

It is made available under a CC-BY-NC-ND 4.0 International license .

195 manuscript but is prohibited by medRxiv. No feature was shared by all subjects, however the 196 features present in more than half of subjects included developmental delay and/or 197 intellectual disability, low growth, and facial dysmorphism. The majority of the typical CdLS 198 facial features and associated malformations were rare or absent in our patient cohort. No low 199 anterior hairline or major limb malformations were reported. Only two individuals had a 200 long/featureless philtrum, one had ptosis, three had confirmed dental anomalies, and one had 201 downturned corners of the mouth. Three individuals had synophrys, three had arched 202 eyebrows, and five had long eyelashes. Three individuals had brachycephaly, three had a thin 203 upper lip, and three had a depressed nasal bridge. Four individuals had cardiac 204 malformations, and two experienced gastroesophageal reflux (GER). Hirsutism was 205 described in three cases. Interestingly, five out of thirteen individuals had a degree of 206 micrognathia/retrognathia. Intellectual disability was present in four individuals and learning 207 disability in an additional one. A delay in reaching developmental milestones was detected in 208 nine individuals. Autistic features were present in three individuals. Photographs were not 209 available for any subject with dysmorphic features.

210 We compared standardized postnatal growth parameters and age at reaching 211 developmental milestones between carriers of SMC3 pLoF variants and 15 cases with pathogenic missense variants or in-frame indels in SMC3 as previously published.¹⁴ A 212 213 difference in standardized birth weight, birth head circumference, postnatal (i.e. at time of 214 enrollment) weight, and postnatal head circumference was detected between the two groups, 215 pLoF variants being associated with less pronounced growth delay than missense/in-frame 216 indel variants, however these differences did not reach a significance threshold of $p \le 0.05$ 217 (Fig. 2a). When comparing the age at achieving developmental milestones, the patients with 218 pLoF variants were able to sit unaided, walk unaided, and speak at a younger age than 219 patients with missense/in-frame indels, although only the difference in age at sitting was

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.23294269; this version posted September 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

significant (p=0.023) (Fig. 2b). pLoF subjects' growth and developmental milestones were
each delayed compared with the population mean in growth and developmental data (Fig. 2).
Thus, in general *SMC3* pLoF variants are associated with a milder phenotype than are
missense variants; however, the spectra are variable and appear to overlap.

- Interestingly, several subjects had other phenotypes with potential biological links to
- 225 SMC3 (see Discussion) including bone marrow failure or leukopenia, acute myeloid leukemia
- 226 (AML), and Coats retinal telangiectasis, however these were limited to a single case each.
- 227 Additional phenotypic and laboratory details, where available, are in the Supplemental Note.
- 228 SMC3 mutational constraint

We were intrigued by subjects who were nonpenetrant for, or had mild presentations of, the above growth and developmental phenotypes given initial metrics suggesting mutational intolerance in this gene. Thus, we sought to further characterize LoF constraint in *SMC3*. Consistent with *in vitro*^{38,39} and model organism studies^{9,10,40,41} indicating *SMC3* is an essential developmental gene, biallelic pLoF variants have never been described in a human being, including our cases.

235 Regarding heterozygous variants, the gnomAD v2.1.1 236 (https://gnomad.broadinstitute.org/) probability of LoF intolerance (pLI) score (evidence for 237 depletion of functional variation from expectation within each gene) and the loss-of-function 238 observed/expected upper bound fraction (LOEUF; a more continuous metric that directly 239 measures the ratios of observed to expected variation) both place SMC3 among the group of 240 genes predicted to be most highly intolerant to LoF variants in a population cohort of adults 241 without severe pediatric disease (pLI = 1; expected/observed ratio of SNV pLoF variants passing filters = 79.5/0; LOEUF 0.04).⁴² In agreement with this, an estimation of the 242 243 probability of haploinsufficiency (pHaplo) of SMC3 based on a machine learning model 244 trained on a broad case-control CNV burden analysis in >950,000 individuals and gene-level

It is made available under a CC-BY-NC-ND 4.0 International license .

features was 0.998 (max score = 1.00);⁴³ of interest, the probability of triplosensitivity (pTriplo) is also very high (0.999). A review of multiple additional databases of control and affected subjects revealed rarity and considerable apparent selection against such alleles (Table S2): No pLoF structural variants are present in gnomAD-SV, and our own CNV analysis of UK Biobank (UKBB) exome data identified only two deletions involving *SMC3* among 196,869 subjects (Fig. S2). pLoF sequence and structural variants are similarly rare or absent in the Database of Genomic Variants (DGV) and DECIPHER (Table S2).

252 To gain insights into the few heterozygous SMC3 pLoF SNV carriers in control 253 populations, who would presumably be nonpenetrant or mildly affected, we cataloged these 254 alleles in gnomAD and the UK Biobank (UKBB) (Fig. 1a; Table S3). The overall frequency 255 of pLoF variants in gnomAD is 6.37E-5 (1/15,699) and in UKBB is 3.32E-5 (1/30,102), and 256 all are singletons. There was neither a strong indication of mosaicism (e.g., low allele 257 balance) nor an age-dependent increase in allele frequency suggestive of clonal 258 hematopoiesis among gnomAD pLoF variants (Fig. S1). Adjudication of the nine gnomAD 259 pLoF variants using the LoF curation framework described above flagged two as not having a 260 LoF effect and an additional two as uncertain or potential technical artifacts (e.g., 261 homopolymer repeat region, lack of read data) (Table S3).

262 Mapping case pLoF SNVs to the SMC3 coding sequence suggested possible 263 clustering toward the 5' half of the transcript (Fig. 1a). To identify gene-level features that 264 would support the veracity and/or biological meaning of such a cluster, we first referenced 265 GTEx (https://gtexportal.org/home/gene/SMC3) and found that the full-length, canonical 266 transcript is the only isoform expressed at an appreciable level in any adult human tissue 267 (Fig. 3a). Further supporting this being the sole isoform, normalized by-exon expression as 268 measured by pext⁴⁴ (obtained via gnomAD) was homogeneous (score=1) across all exons in 269 every GTEx tissue. Next, we investigated whether the existence of SMC3P1, a homologous

It is made available under a CC-BY-NC-ND 4.0 International license .

270 pseudogene at 2q11.2 that is likely the result of retrotransposition of approximately the last 5 271 exons of SMC3 (Fig. 1a), might be impairing variant mapping in that region resulting in an 272 artifactual depletion of 3' variants. However, per-base mean depth of coverage among 273 gnomAD exomes and genomes is similar across the entirety of SMC3 274 (https://gnomad.broadinstitute.org/gene/ENSG00000108055?dataset=gnomad r2 1), and 275 SMC3 pLoF variants in gnomAD/UKBB (Fig. 1a) and somatic SMC3 pLoF variants in 276 tumors from the NCI GDC collection (Fig. 1b) show an even spread across the gene. Finally, 277 we calculated regional missense constraint scores across SMC3 (Fig. 1c); while constraint 278 scores are slightly higher at the 5' end, the entire gene is substantially missense constrained 279 (o/e = 0.28 (0.25 - 0.32); Z=6.4). These data argue against any meaningful clustering of pLoF 280 SNVs.

281 Potential explanations for mild phenotypes and nonpenetrance

282 Having made a strong case for intolerance to heterozygous LoF of SMC3, we 283 continued to seek to explain cases with mild or nonpenetrant developmental and/or growth 284 phenotypes. One potential explanation is mosaicism. Thus, we assessed inheritance and allele 285 balance among our enrolled cases. Variants were inherited in three cases and thus by 286 definition germline mutations in those probands. No case variants were signed out by clinical 287 labs as having allele fractions suggestive of mosaicism. Furthermore, in one subject lacking 288 growth or developmental delay, we identified the mutant allele in three separate tissues (bone 289 marrow, skin biopsy, and blood) with a near-50% allele balance (Supplemental Note).

Another potential explanation for mildly- or un-affected individuals with variants in considerably haploinsufficient genes is that they are dominant infertility/subfertility genes. Indeed, testis and ovary are the adult human tissues with highest relative expression of *SMC3* (<u>https://gtexportal.org/home/gene/SMC3</u>). Yet, *SMC3* has never been identified as a human infertility gene, including the most recent large study of primary ovarian insufficiency,⁴⁵ and

It is made available under a CC-BY-NC-ND 4.0 International license .

295 we identified one maternally transmitted SMC3 pLoF variant. We tested an alternative 296 hypothesis that heterozygous LoF of SMC3 might cause male infertility. We evaluated WES 297 data from >1,000 individuals with non-obstructive azoospermia (NOA) in the GEMINI Phase I cohort⁴⁶ and >1200 additional exomes in a Phase II cohort (some of which were 298 299 normozoospermic male controls and female infertility cases). No SMC3 pLoF variants and 300 only one missense variant with CADD score ≥ 25 were identified (Table S4). Additionally, 301 we assessed rare (gnomAD MAF <1%) coding variants in the Male Reproductive Genomics 302 (MERGE) cohort,⁴⁷ consisting of 2,100 exomes of infertile men with severe oligo-, crypto- or 303 azoospermia. One pLoF and three missense variants with CADD ≥ 25 were identified (Table 304 S4). MERGE missense variants were not enriched when compared with gnomAD variants 305 with CADD ≥ 25 (p=0.612, 2-sample chi-squared test with continuity correction). Finally, 306 among our cases were two paternally inherited variants.

307 *Functional effect*

We next sought to determine whether pLoF *SMC3* variants act as true LoF alleles and have broader functional genomic effects. As subject cell lines and RNA were not available, pLoF *SMC3* variants were identified among hematopoietic and lymphoid tumors from the Cancer Cell Line Encyclopedia (CCLE) with available RNA sequencing data; these led to a significant decrease in *SMC3* gene expression compared to tumors wild-type for *SMC3* (p=0.019, Mann-Whitney U test) (Fig. 3b).

To determine whether decreasing *SMC3* expression is likely to effect a molecular (transcriptomic) signature and to what extent this matches that of other CdLS/cohesinopathy genes, we analyzed Perturb-seq data from Replogle et al³⁶. This resource employed multiplexed CRISPR interference followed by single cell RNA-sequencing. In a genomewide experiment in K562 chronic myelogenous leukemia cells, cells receiving *SMC3*targeting guide RNAs reduced *SMC3* expression to 68.5% residual and exhibited a

It is made available under a CC-BY-NC-ND 4.0 International license .

320 transcriptomic signature of several hundred up- and down-regulated genes (Table S6). The 321 expression profile of SMC3 knockdown was highly correlated with the knockdown profiles 322 of other cohesin ring components (SMC1A, RAD21, STAG2) and the cohesin loading 323 machinery (NIPBL, MAU2) (Fig. 3e). This correlation held true in separate Perturb-seq 324 experiments targeting only essential genes in K562 or retinal pigment epithelium (RPE1) 325 cells (Fig. S3). The data were also able to show a threshold above which SMC3 knockdown – 326 despite cohesin being involved in chromosome segregation - does not result in chromosome instability, similar to other cohesin genes (Table S6) and previous studies involving SMC3.⁴⁸ 327

 $Smc3^{+/-}$ mice were previously shown to possess differences in P1-21 cortical gene expression,⁸ in addition to behavioral differences. Despite substantial methodologic differences – for example age at tissue harvest, which is associated with significant changes in cohesin level⁸ – we ventured to compare these differentially expressed genes to those observed in a study of E17.5 *Nipb1*^{+/-} mouse whole brain, a model of typical CdLS.³⁷ No significant overlap was observed (Fig. 3c).

Finally, we sought to determine whether *SMC3* pLoF variants result in changes to the epigenome matching those of previously-described subjects with CdLS including individuals with missense and in-frame indel variants in *SMC3*, although largely driven by other CdLS genes.¹⁹ Methylation analysis of blood DNA from one available subject (p.Arg360Ter) did not match that episignature (Fig. 4).

339 Discussion

While heterozygous *SMC3* missense and in-frame indel variants are a cause of atypical Cornelia de Lange syndrome (CdLS), and somatic *SMC3* predicted loss-of-function (pLoF) variants are found in cancers, the consequence of germline *SMC3* LoF variants in

It is made available under a CC-BY-NC-ND 4.0 International license .

humans has remained solely in the realm of speculation. The present study was aimed atresolving this question.

345 *Clinical phenotype*

346 The SMC3 pLoF cases presented here demonstrate that this variant type also 347 contributes to a disease phenotype. Published SMC3 missense and in-frame indel cases with 348 atypical CdLS demonstrate growth retardation, developmental delay, and characteristic facial features.¹⁴ We found that pLoF patients share these features, although by quantitative 349 350 comparisons appear on average to have a milder – although overlapping – phenotype than 351 those with missense/in-frame indel variants and would for the most part not be considered to 352 have CdLS, which might explain the near-absence of SMC3 pLoF variants among previously 353 sequenced CdLS cohorts (Fig. 5). Furthermore, the phenotype is variable, with some subjects 354 showing more severe growth or developmental delays and others being nonpenetrant for these key features. Of note, $Smc3^{+/-}$ mice have demonstrated neuronal, behavioral, growth, 355 356 and craniofacial features.^{8,9}

The pathogenesis of CdLS in previously-reported *SMC3* missense/in-frame cases has been suggested to be dominant negative, involving aberrant pairing of mutant SMC3 with other components of the cohesin ring.^{17,18} Our data suggest that, by contrast, a relative shortage of SMC3 has a less severe impact on cohesin function, which suggests that allelespecific therapy to knock down dominant negative alleles – even completely – should be further explored. Nullimorphic and hypomorphic *SMC3* missense variants likely also exist and will be identified as such with further study (Fig. 5).

364 *Deletions involving* SMC3

In the four patients with deletions at 10q25.2, *SMC3* is not the only gene involved in the rearrangement (Fig. 1d) and it is therefore possible that haploinsufficiency for other genes

in the region is causative for some aspects of their phenotype. A small number of genes in these intervals have been associated with dominant human disease, among which only heterozygous *SHOC2* and *SMC3* pathogenic variants cause dysmorphic features and developmental delay; however, the only known pathogenic *SHOC2* variant which causes Noonan-like syndrome with loose anagen hair (OMIM #607721) is missense. Previously reported 10q25.2 deletions detected by cytogenetic methods do not seem to be associated with CdLS-like facial features.^{49,50}

Missense variants in RBM20, which is deleted in all four deletion cases, are associated with a form of dilated cardiomyopathy.⁵¹ No patients in our study with deletions encompassing RBM20 had any sign of cardiomyopathy. The small deletion which only contains *SMC3* and *RBM20* in one subject was of particular interest, as it was also detected in the subject's father who was reported to be healthy with no mention of heart disease.

379 Potential explanations for mild/nonpenetrant cases despite LoF constraint

380 Analyses of multiple population genomic analyses suggested that SMC3 is 381 substantially LoF-, missense-, and even duplication-constrained. Given substantial LoF 382 constraint, it was then potentially surprising that we identified some individuals as having 383 milder features as well as pLoF individuals in gnomAD and UKBB (albeit at a low allele 384 frequency). Of note, constraint metrics are indicative of overall selective pressure rather than observable phenotypic severity,⁵² and the above scenario has been described for other, 385 similarly LoF-constrained disease genes (e.g. ASXL3, ARID1B and AUTS2).⁵³ Nonetheless. 386 387 we sought to investigate potential alternative explanations:

Obligatory postzygotic mosaicism is seen in disorders for which germline pathogenic variation is lethal.⁵⁴ Mosaicism restricted to the blood lineage may be related to clonal hematopoiesis in aging,⁵⁵ which can be caused by somatic variants in a number of cohesin and related genes (e.g. *RAD21*, *SMC1A*, *STAG2*, *CTCF*)⁵⁶. However, somatic *SMC3*

It is made available under a CC-BY-NC-ND 4.0 International license .

pathogenic variants have not previously been associated in isolation with clonal
hematopoiesis,¹² and we found no evidence for mosaicism in our cases or in the few pLoF
variants in gnomAD.

395 In mice, sufficient SMC3 protein is required in oocytes for early embryonic development,¹⁰ and heterozygous depletion of *SMC3* in female mice has deleterious impacts 396 on both the integrity and transmission of zygotic chromosomes.^{9,10,12} Furthermore, 397 conditional knockout of HDAC8, an SMC3 recycling factor, causes subfertility.⁵⁷ Finally. 398 399 several cohesin or cohesin-related genes have been implicated in infertility in humans (REC8, SMC1B, STAG3, SGO2).⁵⁸ Yet, there is no published evidence of SMC3 being involved in 400 401 female infertility and our own analyses identified only rare SMC3 pLoF variants among male 402 infertility (azoospermia) cases and no statistical enrichment of predicted damaging missense 403 variants.

404 *Case-control phenotype associations*

405 SMC3 deletions or pLoF (frameshift, stop gain, splice site) variants have not 406 previously been found to be associated with disease in large case-control studies. For 407 example, there were no control deletions or case deletions <1Mb in a large study generating a copy-number variant 'morbidity map' of individuals with developmental delay,⁵⁹ and only 408 409 one protein truncating variant (included in the present manuscript) was found among DDD study data.⁶⁰ The UK Biobank (UKBB) demonstrates only one moderately significant 410 411 corpuscular phenotypic association for pLoF variants (mean volume) (https://app.genebass.org/gene/ENSG00000108055)⁶¹. Intriguingly, in an analysis of >31k 412 413 individuals with neurodevelopmental phenotypes and their family members, de novo variants 414 in SMC3 were found to be associated with developmental delay (false discovery rate = 3.46E-7), although driven mostly by missense variants.⁶² The lack of phenotypic associations with 415

It is made available under a CC-BY-NC-ND 4.0 International license .

416 *SMC3* pLoF variants in large cohorts could be on account of a lack of true association and/or

- 417 lack of power owing to the rarity of these variants.
- 418 *The possibility of pleiotropic phenotypes*

419 Several patients had intriguing 'other' phenotypes with rational potential links to 420 SMC3: 1) One subject had cytopenias and somewhat low telomere length, while being 421 otherwise remarkably healthy with no intellectual disability, facial dysmorphisms, or other 422 phenotypes consistent with CdLS (Table 1, Supplemental Note). Another subject also had 423 leukopenia. This is of interest on account of poor hematopoietic replicative potential across serial transplantation experiments in $Smc3^{+/-}$ mice and experiments showing that SMC3 424 mutant human cells are out-competed by normal cells;¹² however, others found increased 425 self-renewal.^{11,63} Poor hematopoietic renewal could also result from telomere dysfunction, 426 and some basic science studies potentially implicate cohesin in telomere biology,⁶⁴ although 427 CdLS patients (mostly with NIPBL variants) do not have short telomeres.⁶⁵ Of note, the 428 429 subject with low telomere length also had a VUS in *RTEL1*, a telomere biology disorder gene 430 (OMIM 608833), that is absent from gnomAD and affects a conserved amino acid, although 431 it was transmitted from his father with normal telomere length. 2) A subject with acute 432 myeloid leukemia is also interesting on account of SMC3 variants seen as secondary hits in this and other types of malignancy.²⁹ 3) Finally, another subject had bilateral Coats disease, 433 434 an ultra-rare, idiopathic retinal telangiectasia leading to intra-retinal and subretinal exudates.^{66,67} Syndromic associations with Coats disease include facioscapulohumeral 435 muscular dystrophy (FSHD); approximately one percent of FSHD1 patients have Coats 436 disease, \sim 1,000 times higher than the general population.⁶⁸ FSHD1 is caused by an autosomal 437 438 dominantly inherited loss of D4Z4 repeats on chromosome 4q35, contracting the array from 11-100 to 1-10 repeats and promoting *DUX4* retrogene mis-expression.^{68,69} The remaining 439 440 five percent of FSHD cases (FSHD2) may be attributed to genetic pathogenic variants that

It is made available under a CC-BY-NC-ND 4.0 International license .

441 lead to repeat-independent hypomethylation of D4Z4 in genes such as SMCHD1 (involved in 442 genome organization) and DNMT3B (a chromatin modifier), also prompting mis-expression of DUX4.^{70,71} Based on the involvement of SMCHD1 and DNMT3B in FSHD, perhaps other 443 444 chromatin modifiers or cohesin genes such as SMC3 may impact 4q35 chromatin 445 decompaction, causing DUX4 mis-expression and leading to FSHD. Unfortunately, 446 additional functional testing to explore this hypothesis (D4Z4 repeat length, D4Z4 447 methylation, 4qA vs B haplotype, telomere length, and genome-wide methylation analyses) 448 were unable to be performed for this subject.

449 Functional effect of heterozygous SMC3 pLoF variants

450 We analyzed hematologic and lymphoid transcriptome data, which suggested that 451 pLoF SMC3 alleles act as LoF alleles at the RNA level. This is in line with in vitro data showing the p.(Arg245Ter) variant causes loss of cohesin assembly.⁶³ Analysis of Perturb-452 453 Seq data demonstrated impeccable grouping of the transcriptomic signature from SMC3 454 knockdown with those of other cohesin ring and cohesin loading genes. An analysis of mouse 455 brain transcriptome data failed to find significant overlap between differentially expressed genes in $Smc3^{+/-}$ and $Nipbl^{+/-}$ mice (a model of classic CdLS); however, substantial 456 457 methodological differences existed between the construction, tissue sampling, RNA 458 preparation, and analyses of these two models. DNA methylation in human blood of an 459 SMC3 pLoF case did not cluster with CdLS subjects on a robust epigenetic analysis platform, yet future work is needed to identify whether SMC3^{+/-} LoF yields its own signature, either 460 461 distinct from or an attenuated version of the CdLS signature.

462 Summary

We demonstrate that *SMC3* pLoF variants are depleted at the population level, yet survivable, and provide evidence that they are associated with developmental phenotypes. In

It is made available under a CC-BY-NC-ND 4.0 International license .

465 most cases it is associated with mild-moderate developmental delay, growth deficiency, 466 and/or facial dysmorphism, although not all individuals displayed these features. On average 467 these variants bear a phenotype milder than but overlapping with that of *SMC3* missense/in-468 frame indel variants present in CdLS cohorts.

While incomplete penetrance for a given disease feature – which we observed in our cohort, is still consistent with substantial population-scale LoF constraint,⁵² we nonetheless tested alternative explanations for this including mosaicism and infertility phenotype, neither of which was confirmed. Thus, an overall moderate-severity, but variable, phenotype is the apparent effect of these variants. Variants in *SMC3* have been seen in cancers, however our data do not suggest that pLoF patients are at risk for cancer; there are not enough data to suggest an association.

There are limitations to our attempt to aggregate a consensus phenotype for this variant type that are not unique among initial descriptions of novel syndromes, including: a moderate number of cases, variable depth of clinical data, the potential for ascertainment bias, and a lack of clinical histories across the full lifespan. Further clarity will be realized with additional cases over time, buoyed by even larger-scale genomic data from emerging cohorts numbering in the millions of participants (e.g. The All of Us Research Program Investigators⁷²).

Finally, our work suggests the existence of additional considerably haploinsufficient genes, LoF of which yield yet-undiscovered mild-moderate or nonspecific phenotypes that will be ascertained only by careful, hybrid studies marrying genomic and patient-level data.

486 Acknowledgements

The authors thank: the patients and families who participated in this study; Dr. JasonFlannick, Emma Sherrill, Minh Nguyen, Aubrie Soucy, and the Cornelia de Lange Syndrome

It is made available under a CC-BY-NC-ND 4.0 International license .

489 Foundation, Inc. for general support of the project; and Drs. Jennifer Gerton, Zuzana 490 Tothova, and Kaitlin Samocha for helpful discussion. P.M.B. is supported by award 491 K08NS117891 from the US National Institute of Neurological Disorders and Stroke 492 (NINDS), and an award from the Boston Children's Hospital Office of Faculty Development. 493 K.N.W.F. and the Clinic for Cornelia de Lange Syndrome and Related Disorders are 494 supported by gifts from Peter and Kathy Wagner and Julie and Frank Mairano. M.E.T, 495 P.M.B., L.W., and D.B-I were supported by grants from the US National Institutes of Health 496 (NIH) (U01HG011755, R01MH115957, HD081256, and P50HD104224). D.B is supported 497 by T32HG002295 from the US National Human Genome Research Institute. S.S. is 498 supported by award K23NS119666 from the US NINDS. T.B.H. is supported by the 499 Deutsche Forschungsgemeinschaft (German Research Foundation) – 418081722, 433158657. 500 Some sequencing and analysis was provided by the Broad Institute Center for Mendelian 501 Genomics and was funded by NIH grants UM1HG008900 and R01HG009141. K.M.B is 502 supported by US National Eye Institute (R01EY026904, R01EY012910, P30EY014104) and 503 the Foundation Fighting Blindness (EGI-GE-1218-0753-UCSD). This work was supported in 504 part by the National Institutes of Health of the United States of America grants 505 R01HD078641 and P50HD096723 to D.F.C. S.B. is supported by the NIHR Manchester 506 Biomedical Research Centre (NIHR203308). A.S. is supported by RC2DK122533. M.S-B 507 was supported by NHLBI R01HL143295. Analysis by E.G., S.T. and A.O'D.L was 508 supported by U01HG0011755 and R01HG009141. This work was supported by the Boston 509 Children's Hospital Rare Disease Cohorts Initiative (CRDC). This study makes use of data 510 generated by the DECIPHER community. A full list of centers who contributed to the 511 generation of the data is available from https://deciphergenomics.org/about/stats and via 512 email from contact@deciphergenomics.org. Funding for the DECIPHER project was 513 provided by Wellcome (grant number WT223718/Z/21/Z).

It is made available under a CC-BY-NC-ND 4.0 International license .

514 **Declaration of Interests**

- 515 M.E.T. is supported by research funding and/or reagents from Illumina Inc.,
- 516 Microsoft Inc., Ionis Therapeutics, and Levo Therapeutics. M.P.N, J.H., and J.J. are
- 517 employees of GeneDx, LLC.

518 Data and Code Availability

519 The published article and its supplement list all datasets analyzed during this study.

|--|

								-					
Case no.	1	2	3	4	5	6	7	8	9	10	11	12	13
Variant type	splice	frameshift	nonsense	nonsense	frameshift	frameshift	nonsense	nonsense	frameshift	whole gene del	whole gene del	whole gene del	whole gene del
Variant	c.430-1G>T p.(?)	c.461dup p.(Arg155GlufsTe r12)	c.661C>T p.(Arg221Ter)	c.1078C>T p.(Arg360Ter)	c.1474_1478del p.(Lys492AlafsTe r5)	c.1539del p.(Asn513LysfsTe r4)	c.1561C>T p.(Arg521Ter)	c.2899C>T p.(Arg967Ter)	c.3646_3647dup p.(Gly1217Metfs Ter39)	arr[GRCh37] 10q25.1q25.2(111 490480_11366838 8)x1	arr[GRCh37] 10q25.1q25.3(106 709945_11846010 0)x1	arr[GRCh37] 10q25.1q25.2(108 508297_11333855 2)x1	arr[GRCh37] 10q25.2(11232300 3_112579895)x1
Inheritance	de novo	u	mat	pat	de novo	u	u	de novo	u	de novo	de novo	not mat	pat
Other			VUS dup 1q22q23.1, pat <i>KMT2D</i> variant			Several other variants, AOH		Short telomeres, RTEL1 VUS		VUS dup at 12q		Inherited chr16 del	Inherited inv(10

521 Table 1. Details of heterozygous SMC3 predicted LoF variants. VUS, variant of uncertain clinical significance. AOH, absence of

522 heterozygosity. Pat, paternal. Mat, maternal. u, unknown/unreported inheritance. Variant nomenclature is based on GenBank accession

523 NM_005445.4

(MANE

Select).



524

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.23294269; this version posted September 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license

Figure 1. SMC3 predicted loss-of-function (pLoF) variants. a. pLoF simple nucleotide variants (SNVs) mapped to the SMC3 protein 525 sequence. Subject cases are in black, top. The c.430-1G>T splice variant immediately precedes exon 8, which if skipped would result in a shift 526 of reading frame, however splicing may be rescued (see text). The p.(Gly1217MetfsTer39) variant is in the final exon and is predicted to escape 527 nonsense mediated decay. gnomAD pLoF variants passing quality filters are in grey, bottom. UKBB pLoF variants are in brown, bottom. 528 Domains via UniProt.⁷³ Arrowhead denotes the C-terminal end (equivalent to codon 211) of the minor transcript described in Fig. 3. Diamond 529 denotes the point after which nonsense mediated decay may be escaped (codon 1176). The 3' region homologous to the SMC3P1 pseudogene 530 531 (codons 974-1217) is in orange. **b.** Somatic SMC3 pLoF SNVs among 13,714 tumors from the NCI GDC collection (https://portal.gdc.cancer.gov/genes/ENSG00000108055). c. Regional missense constraint over SMC3, via an analysis of gnomAD. The 532 transition point is in codon 390 (exon 13 of 29). d. Case deletions (based on genome build GRCh37/hg19). Of the OMIM phenotype-associated 533 534 genes in this region (green), none are dominant haploinsufficient disease genes for disorders that include developmental delay or dysmorphic 535 features.





Figure 2. Growth and developmental milestones associated with *SMC3* pLoF compared with pathogenic missense/in-frame indels. a. Growth measurements adjusted for age and sex (Z-score) are shown for *SMC3* predicted loss-of-function (LoF) and missense/in-frame indel cases. 'Postnatal' measurements are at the time of study enrollment/sampling. b. Age at

541	which developmental m	ilestones were reach	ned for the two categories	of SMC3 variants (LoF
542	vs pathogenic missense,	/in-frame indel). 25 ^t	th/50 th /75 th centiles of pop	ulation data (Denver II,
543	via DECIPHER) are sh	own at the right of	each figure in (b). Misso	ense/in-frame indel data
544	were obtained from ¹⁴ .	Plots are standard	boxplots. Statistical com	parisons are the Mann-
545	Whitney	U	test	(Wilcoxon).



It is made available under a CC-BY-NC-ND 4.0 International license

Figure. 3. Gene expression in wild-type and SMC3 ^{+/-} tissues. a. GTEx data demonstrate that only a single, full-length SMC3 isoform
(ENST00000361804.4) is expressed at an appreciable level in any adult human tissue represented (<u>https://gtexportal.org/home/gene/SMC3</u>). b.
pLoF SMC3 variants (LoF; nonsense, frameshift indel, splice site) in hematopoietic and lymphoid tumors correlate with decreased SMC3 gene
expression, to a mean of 71.9% of wild-type (wt) (p=0.019, Mann-Whitney U test). Data derived from the Cancer Cell Line Encyclopedia
(CCLE) (<u>http://xenabrowser.net</u>). c-d. Comparison of genes with altered expression in early postnatal $Smc3^{+/-}$ mouse cortex ⁸ and those altered in
a late prenatal Nipbl ^{+/-} mouse whole brain. ³⁷ c. 50 of 406 (12.3%) differentially expressed genes (DEGs) any age (P1, P3, P7, P14, P21) in
$Smc3^{+/-}$ mice overlap with 3,507 DEGs in E17.5 $Nipbl^{+/-}$ mice (top). 9 of 58 (15.5%) DEGs in 2+ ages in $Smc3^{+/-}$ mice overlap with those same
3,507 genes (bottom). d. Neither of these is significantly different from chance (3,507/30,686 total genes; 11.4%) (any age p=0.632, chi-squared
test of proportions; 2+ ages p=0.441). See Methods for derivation of denominator of 30,686 genes and Discussion for a commentary on
methodological differences between the two models. e. Minimal displacement embedding of pseudobulk-averaged, z-normalized expression
profiles from a genome-wide Perturb-seq experiment in K562 CML cells ³⁶ (plot generated via https://gwps.wi.mit.edu/). Each dot is one of 1,973
genes with strong transcriptomic signatures. The SMC3 knockdown transcriptional disturbances group tightly with those of other cohesin genes
(pink) and even an epigenetic regulator occasionally mutated in CdLS-like patients (EP300).

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 4. Global DNA methylation pattern of *SMC3* **pLoF compared with that of CdLS.** Multidimensional scaling (MDS) plot of global methylation signature (episignature) of blood-derived DNA. A *SMC3* pLoF subject (p.Arg360Ter, purple) does not plot with individuals clinically diagnosed with CdLS (red), instead plotting among the control population (green).



564 Figure 5. Hypothesized phenotypic spectra of SMC3 variant types. Missense (ms) /in-565 frame (i.f.) indel variants, via an apparent dominant negative mechanism as supported by 566 prior literature, carry the most severe phenotype, with many patients appearing to have 567 atypical Cornelia de Lange syndrome (CdLS). Loss-of-function (LoF) variants carry a milder 568 phenotype, with only some individuals being recognized to have CdLS and some individuals 569 lacking key phenotypic features (growth retardation, developmental delay, characteristic 570 facial dysmorphism). We hypothesize that nullimorphic ms and hypomorphic ms variants 571 also exist.

It is made available under a CC-BY-NC-ND 4.0 International license .

572 **References**

573	1	Hoencamp, C. & Rowland, B. D. Genome control by SMC complexes. Nat Rev Mol Cell
574		<i>Biol</i> (2023). <u>https://doi.org:10.1038/s41580-023-00609-8</u>
575	2	Peters, J. M., Tedeschi, A. & Schmitz, J. The cohesin complex and its roles in
576		chromosome biology. <i>Genes Dev</i> 22 , 3089-3114 (2008).
577		https://doi.org:10.1101/gad.1724308
578	3	Nasmyth, K. & Haering, C. H. Cohesin: its roles and mechanisms. Annu Rev Genet 43,
579		525-558 (2009). <u>https://doi.org:10.1146/annurev-genet-102108-134233</u>
580	4	Nagao, K., Adachi, Y. & Yanagida, M. Separase-mediated cleavage of cohesin at
581		interphase is required for DNA repair. <i>Nature</i> 430 , 1044-1048 (2004).
582		https://doi.org:10.1038/nature02803
583	5	Rao, S. S. P. et al. Cohesin Loss Eliminates All Loop Domains. Cell 171, 305-320 e324
584		(2017). https://doi.org:10.1016/j.cell.2017.09.026
585	6	Wendt, K. S. et al. Cohesin mediates transcriptional insulation by CCCTC-binding
586		factor. <i>Nature</i> 451 , 796-801 (2008). https://doi.org:10.1038/nature06634
587	7	Parelho, V. et al. Cohesins functionally associate with CTCF on mammalian
588		chromosome arms. <i>Cell</i> 132 , 422-433 (2008).
589		https://doi.org:10.1016/j.cell.2008.01.011
590	8	Fujita, Y. et al. Decreased cohesin in the brain leads to defective synapse
591		development and anxiety-related behavior. <i>J Exp Med</i> 214 , 1431-1452 (2017).
592		https://doi.org:10.1084/jem.20161517
593	9	White, J. K. <i>et al.</i> Genome-wide generation and systematic phenotyping of knockout
594		mice reveals new roles for many genes. Cell 154, 452-464 (2013).
595		https://doi.org:10.1016/j.cell.2013.06.022
596	10	Yueh, W. T., Singh, V. P. & Gerton, J. L. Maternal Smc3 protects the integrity of the
597		zygotic genome through DNA replication and mitosis. Development 148 (2021).
598		https://doi.org:10.1242/dev.199800
599	11	Viny, A. D. et al. Dose-dependent role of the cohesin complex in normal and
600		malignant hematopoiesis. J Exp Med 212 , 1819-1832 (2015).
601		https://doi.org:10.1084/jem.20151317
602	12	Wang, T. et al. Smc3 is required for mouse embryonic and adult hematopoiesis. Exp
603		<i>Hematol</i> 70 , 70-84 e76 (2019). <u>https://doi.org:10.1016/j.exphem.2018.11.008</u>
604	13	Deardorff, M. A. et al. Mutations in cohesin complex members SMC3 and SMC1A
605		cause a mild variant of cornelia de Lange syndrome with predominant mental
606		retardation. <i>Am J Hum Genet</i> 80 , 485-494 (2007). <u>https://doi.org:10.1086/511888</u>
607	14	Gil-Rodriguez, M. C. et al. De novo heterozygous mutations in SMC3 cause a range of
608		Cornelia de Lange syndrome-overlapping phenotypes. Hum Mutat 36, 454-462
609		(2015). https://doi.org:10.1002/humu.22761
610	15	Ansari, M. et al. Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and
611		CdLS-like phenotypes with observed and predicted levels of mosaicism. J Med Genet
612		51, 659-668 (2014). <u>https://doi.org:10.1136/jmedgenet-2014-102573</u>
613	16	Yuan, B. et al. Global transcriptional disturbances underlie Cornelia de Lange
614		syndrome and related phenotypes. J Clin Invest 125, 636-651 (2015).
615		https://doi.org:10.1172/JCI77435

616	17	Revenkova, E. et al. Cornelia de Lange syndrome mutations in SMC1A or SMC3 affect
617		binding to DNA. <i>Hum Mol Genet</i> 18 , 418-427 (2009).
618		https://doi.org:10.1093/hmg/ddn369
619	18	Gimigliano, A. et al. Proteomic profile identifies dysregulated pathways in Cornelia
620		de Lange syndrome cells with distinct mutations in SMC1A and SMC3 genes. J
621		Proteome Res 11, 6111-6123 (2012). https://doi.org:10.1021/pr300760p
622	19	Aref-Eshghi, E. et al. Evaluation of DNA Methylation Episignatures for Diagnosis and
623		Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders. Am J Hum
624		Genet 106, 356-370 (2020). https://doi.org:10.1016/j.ajhg.2020.01.019
625	20	Gillis, L. A. et al. NIPBL mutational analysis in 120 individuals with Cornelia de Lange
626		syndrome and evaluation of genotype-phenotype correlations. Am J Hum Genet 75 ,
627		610-623 (2004). https://doi.org:10.1086/424698
628	21	Tonkin, E. T., Wang, T. J., Lisgo, S., Bamshad, M. J. & Strachan, T. NIPBL, encoding a
629		homolog of fungal Scc2-type sister chromatid cohesion proteins and fly Nipped-B. is
630		mutated in Cornelia de Lange syndrome. <i>Nat Genet</i> 36 . 636-641 (2004).
631		https://doi.org:10.1038/ng1363
632	22	Yan, J. et al. Mutational and genotype-phenotype correlation analyses in 28 Polish
633		patients with Cornelia de Lange syndrome. Am J Med Genet A 140 , 1531-1541
634		(2006) https://doi.org/10.1002/aimg.a.31305
635	23	Oguni H et al A missense variant of SMC1A causes periodic pharmaco-resistant
636	20	cluster seizures similar to PCDH19-related enilensy. <i>Enilensy Res</i> 155 106149 (2019)
637		https://doi.org/10.1016/i.enlensvres.2019.06.001
638	24	Mannini Liu Krantz D & Music A Spectrum and consequences of SMC1A
639	2 1	mutations: the unexpected involvement of a core component of cohesin in human
640		disease Hum Mutat 31 5-10 (2010) https://doi.org/10.1002/humu.21129
641	25	Di Nardo M Pallotta M M & Musio A The multifaceted roles of cohesin in
642	23	cancer / Exp. Clin. Cancer Res. 41, 96 (2022) https://doi.org/10.1186/s13046-022-
643		02321-5
644	26	Han C et al Characteristics of Cohesin Mutation in Acute Myeloid Leukemia and Its
645	20	Clinical Significance Front Oncol 11 579881 (2021)
646		https://doi.org/10/3389/fonc/2021/579881
647	27	Labuhn M et al Mechanisms of Progression of Myeloid Preleukemia to
648	27	Transformed Myeloid Leukemia in Children with Down Syndrome Cancer Cell 36
640 640		123 138 o110 (2019) https://doi.org/10.1016/j.ccoll.2019.06.007
650	28	Voshida K et al. The landscape of somatic mutations in Down syndrome related
651	20	myoloid disorders. Nat Canot 4E , 1202 1200 (2012) https://doi.org/10.1028/ng.2750
653	20	lang L C & Tethewa 7 Cabacin mutations in muslaid malignancies <i>Bland</i> 129 640
052	29	Jann, J. C. & Totnova, Z. Conesin mutations in myeloid maignancies. <i>Biodu</i> 156 , 649-
055	20	661 (2021). <u>https://doi.org.t0.1182/biood.2019004259</u>
654 CEE	30	Landrum, IVI. J. & Kattman, B. L. Clinvar at five years: Delivering on the promise. Hum
655	24	Mutat 39 , 1623-1630 (2018). <u>https://doi.org/10.1002/humu.23641</u>
656	31	Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching tool
657		for connecting investigators with an interest in the same gene. Hum Mutat 36 , 928-
658 650	22	930 (2015). <u>https://doi.org:10.1002/humu.22844</u>
659	32	KOCKOWITZ, S. et al. Children's rare disease cohorts: an integrative research and
660		clinical genomics initiative. NPJ Genom Med 5, 29 (2020).
661		<u>https://doi.org:10.1038/s41525-020-0137-0</u>

662	33	Pais, L. S. et al. seqr: A web-based analysis and collaboration tool for rare disease
663		genomics. <i>Hum Mutat</i> 43 , 698-707 (2022). <u>https://doi.org:10.1002/humu.24366</u>
664	34	Firth, H. V. et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in
665		Humans Using Ensembl Resources. Am J Hum Genet 84 , 524-533 (2009).
666		<u>https://doi.org:10.1016/j.ajhg.2009.03.010</u>
667	35	Wright, C. F. et al. Non-coding region variants upstream of MEF2C cause severe
668		developmental disorder through three distinct loss-of-function mechanisms. Am J
669		Hum Genet 108, 1083-1094 (2021). <u>https://doi.org:10.1016/j.ajhg.2021.04.025</u>
670	36	Replogle, J. M. et al. Mapping information-rich genotype-phenotype landscapes with
671		genome-scale Perturb-seq. <i>Cell</i> 185 , 2559-2575 e2528 (2022).
672		https://doi.org:10.1016/j.cell.2022.05.013
673	37	Kean, C. M. et al. Decreasing Wapl dosage partially corrects embryonic growth and
674		brain transcriptome phenotypes in Nipbl(+/-) embryos. <i>Sci Adv</i> 8 , eadd4136 (2022).
675		https://doi.org:10.1126/sciadv.add4136
676	38	Robison, B., Guacci, V. & Koshland, D. A role for the Smc3 hinge domain in the
677		maintenance of sister chromatid cohesion. <i>Mol Biol Cell</i> 29 , 339-355 (2018).
678		<u>https://doi.org:10.1091/mbc.E17-08-0511</u>
679	39	Zhang, J. et al. Acetylation of Smc3 by Eco1 is required for S phase sister chromatid
680		cohesion in both human and yeast. <i>Mol Cell</i> 31 , 143-151 (2008).
681		<u>https://doi.org:10.1016/j.molcel.2008.06.006</u>
682	40	Banerji, R., Skibbens, R. V. & Iovine, M. K. Cohesin mediates Esco2-dependent
683		transcriptional regulation in a zebrafish regenerating fin model of Roberts Syndrome.
684		Biol Open 6 , 1802-1813 (2017). <u>https://doi.org:10.1242/bio.026013</u>
685	41	Ghiselli, G. SMC3 knockdown triggers genomic instability and p53-dependent
686		apoptosis in human and zebrafish cells. <i>Mol Cancer</i> 5, 52 (2006).
687		https://doi.org:10.1186/1476-4598-5-52
688	42	Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation
689		in 141,456 humans. Nature 581, 434-443 (2020). https://doi.org:10.1038/s41586-
690		<u>020-2308-7</u>
691	43	Collins, R. L. et al. A cross-disorder dosage sensitivity map of the human genome. Cell
692		185, 3041-3055 e3025 (2022). <u>https://doi.org:10.1016/j.cell.2022.06.036</u>
693	44	Cummings, B. B. et al. Transcript expression-aware annotation improves rare variant
694		interpretation. Nature 581, 452-458 (2020). https://doi.org:10.1038/s41586-020-
695		<u>2329-2</u>
696	45	Ke, H. et al. Landscape of pathogenic mutations in premature ovarian insufficiency.
697		Nat Med 29 , 483-492 (2023). <u>https://doi.org:10.1038/s41591-022-02194-3</u>
698	46	Nagirnaja, L. et al. Diverse monogenic subforms of human spermatogenic failure. Nat
699		Commun 13, 7953 (2022). <u>https://doi.org:10.1038/s41467-022-35661-z</u>
700	47	Wyrwoll, M. J. et al. Genetic Architecture of Azoospermia-Time to Advance the
701		Standard of Care. <i>Eur Urol</i> 83 , 452-462 (2023).
702		<u>https://doi.org:10.1016/j.eururo.2022.05.011</u>
703	48	Deardorff, M. A. et al. HDAC8 mutations in Cornelia de Lange syndrome affect the
704		cohesin acetylation cycle. <i>Nature</i> 489 , 313-317 (2012).
705		https://doi.org:10.1038/nature11316
706	49	Irving, M. et al. Deletion of the distal long arm of chromosome 10; is there a
707		characteristic phenotype? A report of 15 de novo and familial cases. Am J Med Genet
708		A 123A , 153-163 (2003). <u>https://doi.org:10.1002/ajmg.a.20220</u>

105	50	Kehrer-Sawatzki, H. <i>et al.</i> Interstitial deletion del(10)(q25.2q25.3 approximately
710		26.11)case report and review of the literature. Prenat Diagn 25, 954-959 (2005).
711		<u>https://doi.org:10.1002/pd.1252</u>
712	51	Lennermann, D., Backs, J. & van den Hoogenhof, M. M. G. New Insights in RBM20
713		Cardiomyopathy. <i>Curr Heart Fail Rep</i> 17 , 234-246 (2020).
714		<u>https://doi.org:10.1007/s11897-020-00475-x</u>
715	52	Fuller, Z. L., Berg, J. J., Mostafavi, H., Sella, G. & Przeworski, M. Measuring
716		intolerance to mutation in human genetics. Nat Genet 51, 772-776 (2019).
717		<u>https://doi.org:10.1038/s41588-019-0383-1</u>
718	53	Ropers, H. H. & Wienker, T. Penetrance of pathogenic mutations in haploinsufficient
719		genes for intellectual disability and related disorders. Eur J Med Genet 58, 715-718
720		(2015). <u>https://doi.org:10.1016/j.ejmg.2015.10.007</u>
721	54	Thorpe, J., Osei-Owusu, I. A., Avigdor, B. E., Tupler, R. & Pevsner, J. Mosaicism in
722		Human Health and Disease. <i>Annu Rev Genet</i> 54 , 487-510 (2020).
723		https://doi.org:10.1146/annurev-genet-041720-093403
724	55	Carlston, C. M. et al. Pathogenic ASXL1 somatic variants in reference databases
725		complicate germline variant interpretation for Bohring-Opitz Syndrome. Hum Mutat
726		38 , 517-523 (2017). <u>https://doi.org:10.1002/humu.23203</u>
727	56	Gudmundsson, S., Carlston, C. M. & O'Donnell-Luria, A. Interpreting variants in genes
728		affected by clonal hematopoiesis in population data. Hum Genet (2023).
729		<u>https://doi.org:10.1007/s00439-023-02526-4</u>
730	57	Singh, V. P., Yueh, W. T., Gerton, J. L. & Duncan, F. E. Oocyte-specific deletion of
731		Hdac8 in mice reveals stage-specific effects on fertility. Reproduction 157, 305-316
732		(2019). <u>https://doi.org:10.1530/REP-18-0560</u>
733	58	Yatsenko, S. A. & Rajkovic, A. Genetics of human female infertilitydagger. Biol Reprod
734		101, 549-566 (2019). <u>https://doi.org:10.1093/biolre/ioz084</u>
735	59	Coe, B. P. et al. Refining analyses of copy number variation identifies specific genes
736		associated with developmental delay. <i>Nat Genet</i> 46 , 1063-1071 (2014).
737		https://doi.org:10.1038/ng.3092
738	60	Kanlanis I et al Evidence for 28 genetic disorders discovered by combining
730		Rapians, J. et al. Evidence for 20 genetic disorders discovered by combining
155		healthcare and research data. <i>Nature</i> 586 , 757-762 (2020).
740		healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5
740 741	61	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5 Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing
740 741 742	61	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). <u>https://doi.org:10.1038/s41586-020-2832-5</u> Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168
740 741 742 743	61	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5 Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). https://doi.org:10.1016/j.xgen.2022.100168
740 741 742 743 744	61	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). <u>https://doi.org:10.1038/s41586-020-2832-5</u> Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). <u>https://doi.org:10.1016/j.xgen.2022.100168</u> Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture
740 741 742 743 744 745	61 62	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). <u>https://doi.org:10.1038/s41586-020-2832-5</u> Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). <u>https://doi.org:10.1016/j.xgen.2022.100168</u> Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022).
740 741 742 743 744 745 746	61 62	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5 Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). https://doi.org:10.1016/j.xgen.2022.100168 Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022). https://doi.org:10.1038/s41588-022-01104-0
740 741 742 743 744 745 746 747	61 62 63	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). <u>https://doi.org:10.1038/s41586-020-2832-5</u> Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). <u>https://doi.org:10.1016/j.xgen.2022.100168</u> Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022). <u>https://doi.org:10.1038/s41588-022-01104-0</u> Mullenders, J. <i>et al.</i> Cohesin loss alters adult hematopoietic stem cell homeostasis,
740 741 742 743 744 745 746 747 748	61 62 63	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5 Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). https://doi.org:10.1016/j.xgen.2022.100168 Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022). https://doi.org:10.1038/s41588-022-01104-0 Mullenders, J. <i>et al.</i> Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. <i>J Exp Med</i> 212 , 1833-1850 (2015).
740 741 742 743 744 745 746 746 747 748 749	61 62 63	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5 Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). https://doi.org:10.1016/j.xgen.2022.100168 Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022). https://doi.org:10.1038/s41588-022-01104-0 Mullenders, J. <i>et al.</i> Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. <i>J Exp Med</i> 212 , 1833-1850 (2015). https://doi.org:10.1084/jem.20151323
740 741 742 743 744 745 746 746 747 748 749 750	61 62 63 64	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). <u>https://doi.org:10.1038/s41586-020-2832-5</u> Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). <u>https://doi.org:10.1016/j.xgen.2022.100168</u> Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022). <u>https://doi.org:10.1038/s41588-022-01104-0</u> Mullenders, J. <i>et al.</i> Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. <i>J Exp Med</i> 212 , 1833-1850 (2015). <u>https://doi.org:10.1084/jem.20151323</u> Remeseiro, S. <i>et al.</i> Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in
740 741 742 743 744 745 746 747 748 747 748 749 750 751	61 62 63 64	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5 Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). https://doi.org:10.1016/j.xgen.2022.100168 Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022). https://doi.org:10.1038/s41588-022-01104-0 Mullenders, J. <i>et al.</i> Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. <i>J Exp Med</i> 212 , 1833-1850 (2015). https://doi.org:10.1084/jem.20151323 Remeseiro, S. <i>et al.</i> Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres. <i>EMBO J</i> 31 , 2076-2089 (2012).
740 741 742 743 744 745 746 747 748 749 750 751 752	61 62 63 64	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5 Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). https://doi.org:10.1016/j.xgen.2022.100168 Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022). https://doi.org:10.1038/s41588-022-01104-0 Mullenders, J. <i>et al.</i> Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. <i>J Exp Med</i> 212 , 1833-1850 (2015). https://doi.org:10.1084/jem.20151323 Remeseiro, S. <i>et al.</i> Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres. <i>EMBO J</i> 31 , 2076-2089 (2012). https://doi.org:10.1038/emboj.2012.11
740 741 742 743 744 745 746 747 748 749 750 751 752 753	61 62 63 64	healthcare and research data. <i>Nature</i> 586 , 757-762 (2020). https://doi.org:10.1038/s41586-020-2832-5 Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. <i>Cell Genom</i> 2 , 100168 (2022). https://doi.org:10.1016/j.xgen.2022.100168 Fu, J. M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nat Genet</i> 54 , 1320-1331 (2022). https://doi.org:10.1038/s41588-022-01104-0 Mullenders, J. <i>et al.</i> Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. <i>J Exp Med</i> 212 , 1833-1850 (2015). https://doi.org:10.1084/jem.20151323 Remeseiro, S. <i>et al.</i> Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres. <i>EMBO J</i> 31 , 2076-2089 (2012). https://doi.org:10.1038/emboj.2012.11 Kline, A. D. <i>et al.</i> Cornelia de Lange syndrome: further delineation of phenotype,

755 756		Symposium abstracts. Am J Med Genet A 164A , 1384-1393 (2014).
757	66	Chang M M McLean I W & Merritt I C Coats' disease: a study of 62
758	00	histologically confirmed cases <i>LPediatr Onbthalmol Strabismus</i> 21 163-168 (1984)
759		https://doi.org/10/3928/0191-3913-19840901-03
760	67	Shields I A Shields C I Honavar S G & Demirci H Clinical variations and
761	07	complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial
762		Lecture $Am = L Ophthalmal 131 - 561-571 (2001) https://doi.org/10.1016/s0002-$
763		9394(00)00883-7
764	68	Statland, J. M. <i>et al.</i> Coats syndrome in facioscapulohumeral dystrophy type 1:
765		frequency and D4Z4 contraction size. <i>Neurology</i> 80 . 1247-1250 (2013).
766		https://doi.org:10.1212/WNI_0b013e3182897116
767	69	Campbell, A. E., Belleville, A. E., Resnick, R., Shadle, S. C. & Tapscott, S. J.
768		Facioscapulohumeral dystrophy: activating an early embryonic transcriptional
769		program in human skeletal muscle. Hum Mol Genet 27 . R153-R162 (2018).
770		https://doi.org:10.1093/hmg/ddy162
771	70	Lemmers, R. J. et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-
772		permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat
773		Genet 44, 1370-1374 (2012). https://doi.org:10.1038/ng.2454
774	71	van den Boogaard, M. L. <i>et al.</i> Mutations in DNMT3B Modify Epigenetic Repression
775		of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy. Am J
776		Hum Genet 98 , 1020-1029 (2016). https://doi.org:10.1016/j.ajhg.2016.03.013
777	72	All of Us Research Program, I. et al. The "All of Us" Research Program. N Engl J Med
778		381 , 668-676 (2019). https://doi.org:10.1056/NEJMsr1809937
779	73	UniProt. C. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res
780		49 , D480-D489 (2021). https://doi.org:10.1093/nar/gkaa1100
781		